Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response

Li, Ruiyu; Liang, Zhiyong

doi:10.1097/cm9.0000000000001097

Cited by 27 publications

(18 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings apply to the connection of ecc-DNA in "oncogene amplification" [34], the generation of tumors [35][36][37][38][39], their pathogenesis [40][41][42], and their acceleration [43].…”

Section: Am J Biomed Sci and Resmentioning

confidence: 95%

Two Sorts of DNA in Eukaryotic Cells: Linear Chromosomal DNA and Circular Extrachromosomal DNA

Dennin

2022

AJBSR

View full text Add to dashboard Cite

In addition to Chromosomal DNA (chr-DNA), eukaryotic cells contain Extrachromosomal DNA (ec-DNA), e.g., Mitochondrial DNA (mt-DNA), and a particular class named Extrachromosomal Circular DNA (ecc-DNA). The ecc-DNA structures harbor functional sequences known to be present in the chr-DNA. Ecc-DNA has many sizes, from thousands of base pairs to mega base pairs. Their proportion of the total cellular DNA can be up to 20%, both in cells from healthy people and people with diseases, for example, cancer. A research focus is an exploration of how ecc-DNA is involved in oncology. The possible influence of ecc-DNA on chromosomal sequences in the Human Genome Project gets addressed.

show abstract

Section: Am J Biomed Sci and Resmentioning

confidence: 95%

Two Sorts of DNA in Eukaryotic Cells: Linear Chromosomal DNA and Circular Extrachromosomal DNA

Dennin

2022

AJBSR

View full text Add to dashboard Cite

show abstract

“…170,171 Circulating tumour DNA is another exciting development, with studies in patients with lung and other cancers demonstrating utility in screening, diagnosis, surveillance and genomic profiling of cancers while reducing the need for repeated invasive investigations. 172,173 Further examples include the use of decisional tools that integrate genomic data to stratify risk and treatment options for patients (eg Oncotype DX ® [Genomic Health] in patients with breast cancer). 174 Outside cancer diagnostics, genome-wide association studies are also influencing our understanding of common conditions such as adhesive capsulitis ('frozen shoulder').…”

Section: B4 Genomics For Surgical Trainees In the 21 St Century Elean...mentioning

confidence: 99%

Future of Surgery: Technology Enhanced Surgical Training: Report of the FOS:TEST Commission

Adebayo¹,

Aldoori²,

Allum³

et al. 2022

View full text Add to dashboard Cite

Over the past 50 years the capability of technology to improve surgical care has been realised and while surgical trainees and trainers strive to deliver care and train; the technological ‘solutions’ market continues to expand. However, there remains no coordinated process to assess these technologies. The FOS:TEST Report aimed to (1) define the current, unmet needs in surgical training, (2) assess the current evidence-base of technologies that may be beneficial to training and map these onto both the patient and trainee pathway and (3) make recommendations on the development, assessment, and adoption of novel surgical technologies. The FOS:TEST Commission was formed by the Association of Surgeons in Training (ASiT), The Royal College of Surgeons of England (RCS England) Robotics and Digital Surgery Group and representatives from all trainee specialty associations. Two national datasets provided by Health Education England were used to identify unmet surgical training needs through qualitative analysis against pre-defined coding frameworks. These unmet needs were prioritised at two virtual consensus hackathons and mapped to the patient and trainee pathway and the capabilities in practice (CiPs) framework. The commission received more than 120 evidence submissions from surgeons in training, consultant surgeons and training leaders. Following peer review, 32 were selected that covered a range of innovations. Contributors also highlighted several important key considerations, including the changing pedagogy of surgical training, the ethics and challenges of big data and machine learning, sustainability, and health economics. This summates to 7 Key Recommendations and 51 concluding statements. The FOS:TEST Commission was borne out of what is a pivotal point in the digital transformation of surgical training. Academic expertise and collaboration will be required to evaluate efficacy of any novel training solution. However, this must be coupled with pragmatic assessments of feasibility and cost to ensure that any intervention is scalable for national implementation. Currently, there is no replacement for hands-on operating. However, for future UK and ROI surgeons to stay relevant in a global market, our training methods must adapt. The Future of Surgery: Technology Enhanced Surgical Training Report provides a blueprint for how this can be achieved.

show abstract

“…17 This technique assesses the release of DNA fragments from tumor cells into the peripheral circulation due to apoptosis and necrosis. 17,[98][99][100] Recent realworld data suggest droplet-digital PCR has high sensitivity and specificity for low-abundance T790M mutation. 18 The NCCN and ESMO guidelines now recommend repeat genomic testing at progression to identify EGFR-and ALK-resistance targets.- 10,14 Newer applications for ctDNA, such as real-time therapy response monitoring, minimal residual disease (MRD) testing, and their use as a predictive biomarkers for immunotherapy, are currently under investigation.…”

Section: Egfr Testingmentioning

confidence: 99%

“…However, tissue samples from biopsies are often insufficient or inadequate for biomarker testing, 86,122,133,136,146 necessitating repeat biopsies and delays in treatment. 100 Optimizing tissue handling after biopsies are obtained to maximize available material for molecular studies is essential, and standardized algorithms for diagnostic procedures should be defined in routine practice. These should involve reflex testing for biomarker testing, which will shorten TAT and preserve tissue.…”

Section: Barriers To Biomarker Testingmentioning

confidence: 99%

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Dalurzo¹,

Avilés‐Salas²,

Soares³

et al. 2021

OTT

View full text Add to dashboard Cite

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements. The presence of these mutations is predictive of response to targeted therapies such as EGFR tyrosine kinase inhibitors (TKIs) and ALK TKIs. However, there are substantial challenges for the implementation of biomarker testing, particularly in emerging countries. Understanding the barriers to testing in NSCLC will be key to improving molecular testing rates worldwide and patient outcomes as a result. In this article, we review EGFR mutations and ALK rearrangements as predictive biomarkers for NSCLC, discuss a selection of appropriate tests and review the literature with respect to the global uptake of EGFR and ALK testing. To help improve testing rates and unify procedures, we review our experiences with biomarker testing in China, South Korea, Russia, Turkey, Brazil, Argentina and Mexico, and propose a set of recommendations that pathologists from emerging countries can apply to assist with the diagnosis of NSCLC.

show abstract

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response

Cited by 27 publications

References 90 publications

Two Sorts of DNA in Eukaryotic Cells: Linear Chromosomal DNA and Circular Extrachromosomal DNA

Two Sorts of DNA in Eukaryotic Cells: Linear Chromosomal DNA and Circular Extrachromosomal DNA

Future of Surgery: Technology Enhanced Surgical Training: Report of the FOS:TEST Commission

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Contact Info

Product

Resources

About